Effectiveness, drug survival and safety of fumaric acid esters for moderate-to-severe psoriasis in routine care: results from the German Psoriasis Registry PsoBest

被引：0
|
作者：
Augustin, M. [1 ]
Mrowietz, U. [2 ]
Radtke, M. A. [3 ]
Thaci, D. [4 ]
Ralph, K.
Koerber, A. [5 ]
Reich, K. [6 ]
机构：
[1] Univ Med Ctr Hamburg, Inst & German Ctr Hlth Serv Res Dermatol, Hamburg, Germany
[2] Univ Kiel, Dept Dermatol, Kiel, Germany
[3] Univ Hamburg, IVDP, Hamburg, Germany
[4] Univ Schleswig Holstein, Dept Dermatol, Lubeck, Germany
[5] Univ Essen Gesamthsch, Dept Dermatol, Essen, Germany
[6] Dermatologikum, Hamburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2017年 / 177卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FC26
引用
收藏
页码：E246 / E247
页数：2
相关论文
共 50 条
  • [21] Effectiveness of guselkumab among patients with moderate-to-severe plaque psoriasis in the Corrona Psoriasis Registry
    Armstrong, April W.
    Callis-Duffin, Kristina
    Fitzgerald, Timothy
    Teeple, Amanda
    Uy, Jonathan
    Olurinde, Mobolaji
    Rowland, Katelyn
    McLean, Robert R.
    Guo, Lin
    Shan, Ying
    Van Voorhees, Abby S.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB122 - AB122
  • [22] Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
    Egeberg, A.
    Ottosen, M. B.
    Gniadecki, R.
    Broesby-Olsen, S.
    Dam, T.
    Bryld, L. E.
    Rasmussen, M. K.
    Skov, L.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E284 - E285
  • [23] Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis
    Egeberg, A.
    Ottosen, M. B.
    Gniadecki, R.
    Broesby-Olsen, S.
    Dam, T. N.
    Bryld, L. E.
    Rasmussen, M. K.
    Skov, L.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (02) : 509 - 519
  • [24] SAFETY IN NATIONAL CARE - REAL WORLD DATA FROM THE GERMAN PSORIASIS-REGISTRY "PSOBEST"
    Rustenbach, S. J.
    Purwins, S.
    Spehr, C.
    Radtke, M. A.
    Reich, K.
    Augustin, M.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A511 - A511
  • [25] Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment
    Leutz, A.
    Pinter, A.
    Thaci, D.
    Augustin, M.
    Schuster, C.
    Fotiou, K.
    Hundemer, H. P.
    Saure, D.
    Mrowietz, U.
    Reich, K.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 548 - 550
  • [26] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [27] Real-world evidence of Guselkumab for the treatment of moderate-to-severe psoriasis: Efficacy and drug survival analysis from the Australasian Psoriasis Registry
    Manuelpillai, Nicholas
    Parikh, Sumit
    Puig, Andrea
    Maranta, Debra
    Foley, Peter
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2022, 63 : 9 - 9
  • [28] Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care
    Ulrich Mrowietz
    Christina Sorbe
    Kristian Reich
    Ralph von Kiedrowski
    Jörg Weckbecker
    Marc A. Radtke
    Stephan J. Rustenbach
    Matthias Augustin
    [J]. European Journal of Dermatology, 2020, 30 : 41 - 48
  • [29] Therapy Duration and Response with Biologics: Results from the German Psoriasis Registry PsoBest
    Mrowietz, U.
    Spehr, C.
    Bohke, W. H.
    Reich, K.
    Radtke, M. A.
    Thaci, D.
    Rustenbach, S. J.
    Augustin, M.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 116 - 116
  • [30] Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care
    Mrowietz, Ulrich
    Sorbe, Christina
    Reich, Kristian
    Von Kiedrowski, Ralph
    Weckbecker, Joerg
    Radtke, Marc A.
    Rustenbach, Stephan J.
    Augustin, Matthias
    [J]. EUROPEAN JOURNAL OF DERMATOLOGY, 2020, 30 (01) : 41 - 48
12345